1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
652DF17368E895560852580430051CF5C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-pharmaceutical-new-product-planning-excellence-market-research-timing-activities?opendocument
18
19opendocument
203.226.251.81
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services New Product Development New Product Planning

Pharmaceutical New Product Planning Excellence: Market Research and Timing of Activities

ID: 5436


Features:

15 Info Graphics

19 Data Graphics

170 Metrics

3 Narratives


Pages/Slides: 43


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Pharmaceutical New Product Planning Excellence: Market Research and Timing of Activities"

STUDY OVERVIEW

The pharmaceutical New Product Planning function conducts activities that create a picture for how a new product will perform in the marketplace if it is approved by the FDA. For instance in the early stages of development, the NPP function will perform patient segmentation research to clarify what patients will benefit most from a potential therapy. Patient segmentation is just one of several types of market research studies that the NPP role will do for products in development.


Best Practices, LLC undertook this benchmarking study to provide NPP leaders with pharma industry benchmarks on when organizations conduct key market research activities for new products. The study also provides an overview of the current state of NPP in pharma and key patterns in NPP activities during the development process.


KEY TOPICS

  • The State of New Product Planning
  • New Product Planning Activities: Key Patterns And Activities
  • New Product Planning Activities: Market Research


KEY METRICS
  • When Does the Transition from New Product Planning to Inline (Brand) Marketing at Your Company Occur?
  • NPP Activities during Each Stage of the Development Process
  • NPP Activities during Phase 2 – Pre-Clinical and Phase 3 - Commercial Hand-off
Timing of Market Research Activities
  • Timing of Exploratory – Disease State/Therapeutic Insight
  • Timing of Patient Segmentation
  • Timing of Patient Flow & Treatment Algorithm
  • Timing of Healthcare Professional Segmentation
  • Timing of Positioning Research
  • Timing of Core Message Development
  • Timing of Draft Launch Label – Market Research
  • Timing of Managed Care Research/Health Outcomes
  • Timing of Pricing – Secondary Data
  • Timing of Pricing – Primary Pricing Research

SAMPLE KEY FINDINGS

  • Market Research Kick-starts in Phase I/II for Global Teams and Phase II/III for Regional Teams: Except for Exploratory Study which starts in phase I, more than half of the global teams start 6 out of 9 market research activities in phase II. These activities are managed care research, patient segmentation, treatment algorithm, healthcare professional segmentation, pricing studies and market research for draft label. Positioning and core message development starts in phase III. More than 70% of regional teams start all but managed care research in phase III. More than 67% of the regional teams start managed care research in phase II.

METHODOLOGY

For this research project, Best Practices, LLC engaged 19 leaders from 15 leading pharmaceutical, biotech, and life sciences companies.

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Medical Device; Biotech; Health Care; Clinical Research; Laboratories; Manufacturing; Consumer Products; Diagnostic


Companies Profiled:
Alkermes; Zydus Cadila; GlaxoSmithKline ; Astellas; Roche; Novartis; Sanofi; Pfizer; Takeda Pharmaceuticals; Cytokinetics; Allergan; Medicago; Bayer; Galderma; Wockhardt

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.